NEW YORK (GenomeWeb News) – Sequenom said today that it has agreed to pay $14 million to shareholders to settle their class action lawsuit against the company.

Sequenom said that the settlement will be funded by insurance proceeds. Additionally, the company has agreed to issue to the plaintiffs a number of shares of Sequenom common stock, to be determined after final approval of the settlement by the US District Court.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.